3.17

2.59% 0.08

After Hours: 3.27 0.10 +3.15%

Xenetic Biosciences Inc (XBIO)

Overview News Price History Financials Discussions Forecast Stock Split

Xenetic Biosciences Inc stock is traded at $3.17, with a volume of 15,069. It is up +2.59% in the last 24 hours and up +0.48% over the past month. Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Previous Close:

$3.09

Open:

$3.09

24h Volume:

15,069

Relative Volume:

0.70

Market Cap:

$7.26M

Revenue:

$2.98M

Net Income/Loss:

$-2.68M

P/E Ratio:

-1.962

EPS:

-1.6157

Net Cash Flow:

$-2.29M

1W Performance:

+5.67%

1M Performance:

+0.48%

6M Performance:

+16.54%

1Y Performance:

+2.26%

1-Day Range:

$3.08

$3.27

1-Week Range:

$2.93

$3.2932

52-Week Range:

$1.90

$13.93

Xenetic Biosciences Inc Stock (XBIO) Company Profile

Name

Xenetic Biosciences Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

781-778-7720

Address

945 CONCORD ST., FRAMINGHAM, MA

Employee

Twitter

@XeneticBio

Next Earnings Date

2026-05-12

Latest SEC Filings

XBIO's Discussions on Twitter

Compare XBIO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XBIO Xenetic Biosciences Inc	3.17	7.08M	2.98M	-2.68M	-2.29M	-1.6157
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-20	Initiated	Maxim Group	Buy

Xenetic Biosciences Inc Stock (XBIO) Latest News

May 03, 2026

Xenetic’s Next Test: An ASCO Readout And The Cash Question - Finimize

May 03, 2026

May 02, 2026

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - Times Herald

May 02, 2026

Apr 25, 2026

Xenetic Biosciences Grants Equity Award to Interim CEO - The Globe and Mail

Apr 25, 2026

Xenetic Biosciences, Inc. Files Form 8-K Announcing Restricted Stock Award Agreement for CEO James Parslow - Minichart

Apr 25, 2026

Xenetic Biosciences, Inc. 2025 Annual Report 10-K/A: Executive Compensation, Governance, and Shareholder Information - Minichart

Apr 25, 2026

Apr 24, 2026

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting - Times Argus

Apr 24, 2026

Xenetic Biosciences (NASDAQ: XBIO) updates CEO pay, ownership in 10-K/A - Stock Titan

Apr 24, 2026

Xenetic Biosciences (NASDAQ: XBIO) grants CEO/CFO 100,000 restricted shares - Stock Titan

Apr 24, 2026

Apr 23, 2026

Xenetic Biosciences (XBIO) interim CEO awarded 100,000-share restricted stock grant - Stock Titan

Apr 23, 2026

Apr 22, 2026

Cancer drug research from Xenetic gets June poster slot at ASCO - Stock Titan

Apr 22, 2026

Apr 21, 2026

Xenetic Biosciences (XBIO) Stock: Pricing Analysis (Momentum Fading) 2026-04-20Resistance Breakout - Xã Vĩnh Công

Apr 21, 2026

Apr 15, 2026